Top Markets
Coin of the day
Mirati Therapeutics, Inc. Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc.

MRTX
株式のランク #5115
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
株価
$58.70
最終同期: 2024-01-23
時価総額
$2.98B
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Mirati Therapeutics, Inc. (MRTX)

カテゴリー

Mirati Therapeutics, Inc.(MRTX)の株価履歴
終値の最高値: $58.94 (2024-01-01)

終値の最安値: $8.67 (2013-07-01)
Mirati Therapeutics, Inc. の株価履歴(2013 ~ 2026)
年間株価パフォーマンス
パフォーマンス
2024 2.02%
2023 12.06%
2022 -63.56%
2021 -39.15%
2020 103.16%
2019 189.49%
2018 132.29%
2017 218.41%
2016 -84.08%
2015 98.82%
2014 1.02%
2013 0.00%
類似企業または競合の株価
企業 株価 変化率 1年%
$549.38 41.20%
US
$1.05K 47.75%
NL
$148.35 491.02%
US
$122.41 -12.81%
AU
$764.47 7.08%
CH